Masumi Ueda Oshima

Masumi Ueda Oshima

Auto-generated profile, based on publicly available information

Masumi Ueda Oshima

Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Journal of the National Comprehensive Cancer Network
Verified
Journal Article
Closed access
PDF file
MUMasumi Ueda
Masumi Ueda
RMRenato Martins
Renato Martins
PHPaul C. Hendrie
Paul C. Hendrie
TMTerry McDonnell
Terry McDonnell
JCJennie R. Crews
Jennie R. Crews
FSF. Marc Stewart
F. Marc Stewart
The first confirmed case of coronavirus disease 2019 (COVID-19) in the United States was reported on January 20, 2020, in Snohomish County, Washington. At the epicenter of COVID-19 in the United States, the Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, and University of Washington are at the forefront of delivering care to patients with cancer during this public health crisis. This Special Feature highlights the unique circumstances and challenges of cancer treatment amidst this global pandemic, and the importance of organizational structure, preparation, agility, and a shared vision for continuing to provide cancer treatment to patients in the face of uncertainty and rapid change.

20 May 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
MLMark J. Levis
Mark J. Levis
MHMehdi Hamadani
Mehdi Hamadani
BLBrent Logan
Brent Logan
RJRichard J Jones
Richard J Jones
ASAnurag K Singh
Anurag K Singh
BIBMT-CTN 1506/MORPHO Study Investigators
BMT-CTN 1506/MORPHO Study Investigators
PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with AML harboring an internal tandem duplication mutation of FLT3 ( FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202 ) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS: Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS: Three hundred fifty-six participants were randomly assigned post-HCT to receive gilteritinib or placebo. Although RFS was higher in the gilteritinib arm, the difference was not statistically significant (hazard ratio [HR], 0.679 [95% CI, 0.459 to 1.005]; two-sided P = .0518). However, 50.5% of participants had MRD detectable pre- or post-HCT, and, in a prespecified subgroup analysis, gilteritinib was beneficial in this population (HR, 0.515 [95% CI, 0.316 to 0.838]; P = .0065). Those without detectable MRD showed no benefit (HR, 1.213 [95% CI, 0.616 to 2.387]; P = .575). CONCLUSION: Although the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.

8 May 2025 in Blood
Verified
Journal Article
Open access
MLMark J. Levis
Mark J. Levis
MHMehdi Hamadani
Mehdi Hamadani
BLBrent R. Logan
Brent R. Logan
RJRichard J. Jones
Richard J. Jones
ASAnurag K. Singh
Anurag K. Singh
YCYi-Bin Chen
Yi-Bin Chen
BMT CTN (Blood and Marrow Transplant Clinical Trials Network) 1506 (“MORPHO”) was a randomized study of gilteritinib compared with placebo as maintenance therapy after hematopoietic cell transplantation (HCT) for patients with FLT3-ITD–mutated acute myeloid leukemia (AML). A key secondary end point was to determine the impact on survival of before and/or after HCT measurable residual disease (MRD), as determined using a highly sensitive assay for FLT3-ITD mutations. Generally, gilteritinib maintenance therapy was associated with improved relapse-free survival (RFS) for participants with detectable peri-HCT MRD, whereas no benefit was evident for those lacking detectable MRD. We conducted a post hoc analysis of the data and found that the level of MRD detected with this approach correlated remarkably with RFS and relapse risk, and that MRD detectable at any level negatively affected RFS. In the placebo arm, 42.2% of participants with detectable FLT3-ITD MRD relapsed compared with 13.4% of those without detectable MRD. We found that 14.8% of participants had multiple FLT3-ITD clones detected as MRD and had worse survival irrespective of treatment arm. Finally, we examined the kinetics of FLT3-ITD clonal relapse or eradication and found that participants on the placebo arm with detectable MRD relapsed rapidly after HCT, often within a few weeks. MRD-positive participants on the gilteritinib arm relapsed either with FLT3 wild-type clones (assessed by capillary electrophoresis), after cessation of gilteritinib with persistent MRD, or on progression of multiclonal disease. These data demonstrate the potential of FLT3-ITD MRD to guide therapy with gilteritinib for this subtype of AML. This trial was registered at www.clinicaltrials.gov as #NCT02997202.

24 January 2023 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
GPGarrett A. Perchetti
Garrett A. Perchetti
MBMelinda A. Biernacki
Melinda A. Biernacki
HXHu Xie
Hu Xie
JCJared Castor
Jared Castor
LJLaurel Joncas-Schronce
Laurel Joncas-Schronce
DZDanniel Zamora
Danniel Zamora

23 February 2024 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
RBRahul Banerjee
Rahul Banerjee
ACAndrew J. Cowan
Andrew J. Cowan
MOMarivel Ortega
Marivel Ortega
CMConstance Missimer
Constance Missimer
PCPaul A. Carpenter
Paul A. Carpenter
CSChristopher Su
Christopher Su

15 November 2024 in Blood Advances
Verified
Journal Article
Open access
PCPaul Andrew Carpenter
Paul Andrew Carpenter
TGTed A. Gooley
Ted A. Gooley
JBJulie Boiko
Julie Boiko
CLCatherine J. Lee
Catherine J. Lee
LBLauri M. Burroughs
Lauri M. Burroughs
SLStephanie Lee
Stephanie Lee
Since 2005, there has been a steady decline in chronic graft-versus-host disease (cGVHD) at the Fred Hutchinson Cancer Center. To better understand this phenomenon, we studied the risk of cGVHD requiring systemic immunosuppression (cGVHD-IS) as a function of hematopoietic cell transplantation (HCT) date in 3066 survivors from 2005 through 2019. Cox regression models were fit to assess associations of HCT date (as a continuous linear variable) with cause-specific hazards of cGVHD using unadjusted and adjusted models. Median follow-up for study subjects was 7.0 years (range, 1.0-17.2). Two-year probabilities of cGVHD-IS declined among all survivors from 45% to 52% (2005-2007) to ∼40% (2008-2012) and then further to ∼26% by 2017. A decline was also observed when the analysis was restricted to 502 pediatric survivors, with cGVHD-IS probabilities <10% since 2013. Among 305 adult and pediatric survivors who underwent transplantation for nonmalignant diseases, cGVHD rates showed greater fluctuation but remained <20% after 2016. Each 5-year increase in HCT date was associated with a 27% decrease in the cause-specific hazard of cGVHD (unadjusted hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.68-0.78; P < .0001); the HR was 0.81 (95% CI, 0.75-0.87; P < .0001) even after adjusting for various factors (age, donor/stem-cell source, race, sex, conditioning intensity, GVHD prophylaxis, among others) that could lead to cGVHD reduction. The decline in cGVHD was not fully explained by demographic shifts and greater use of HCT approaches that are generally associated with lower cGVHD rates. This observation underscores that single-cohort cGVHD prevention studies should use contemporaneous and not historical controls for comparison.